RESUMO
Background: The Drug utilization research (DUR) compares drug use between different countries and regions and is used to assess the rationality of prescribing pattern of the drug therapy. With this background we decided to evaluate antipsychotic drugs prescribing pattern in the psychiatric patients in a tertiary care hospital.Methods: The study was carried out at Department of Psychiatry, DSMCH. It was open label, cross - sectional, prescribed Documents based study. Duration of the study was one month (May-2017). Out-Patient number, age, sex, diagnosis, prescribed generic name, brand name, dose, route of administration, duration of therapy obtained from the Prescription register of Out - Patient Department of the Psychiatry.Results: The clinical experiences of the Psychiatrist I, II and III were 17 years, 35 years and 10 years respectively. The Psychiatrist I, II and III prescribed treatment for 36 (31.9%), 61 (54%) and 16 (14.2%) patients respectively. Among overall (n=113) patients (average age 38.9 years), male n=56 (49.6%) and female=57 (50.4%) were treated by all the three psychiatrists. The percentage of prescription of various drugs used were: Escitalopram (15.7%), Clonazepam (14.6%), Sertraline (8.7%), Risperidone (7.5%), Propranolol (6.7%), Olanzapine (6.3%), Quetiapine (5.9%), Trihexyphenidyl (5.5%), Amitriptyline (5.1%) and Other prescribed drugs, were between (0.4 to 2.8%).Conclusions: From this study, it can conclude that rational usage of drugs were followed in this study. All three prescribers (Psychiatrist I, II, and III) prescriptions were found to be rationale.
RESUMO
The purpose of the present study was to prepare and evaluate rod shaped biodegradable implants of gentamicin sulfate using poly[epsilon-caprolactone] [PCL]. The implants were prepared by melt extrusion method with different ratios of drug and PCL [1:1, 1:1.5 and 1:2] and evaluated for drug content, in vitro drug release, stability studies and in vivo evaluation in healthy rabbits. The implants were found to be uniform with respect to weight, diameter, length and drug content. In the in vitro drug release studies, implants released the drug in a biphasic pattern with an initial burst release followed by a slow release over a period of 80 days. In the in vivo experiment, the gentamicin concentration of bone was maintained above the minimum inhibitory concentration for Staphylococcus aureus over a period of 4 weeks. In the stability studies, the implants exhibited no change in the drug content after 6 months at refrigeration temperature and 25°C. The present study reveals the applicability of biodegradable gentamicin implants to treat bone disorders